Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma - Takeaways - MDSpire

Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma

  • By

  • F. Schwarz

  • L. Levien

  • M. Maulhardt

  • G. Wulf

  • N. Brökers

  • E. Aydilek

  • February 3, 2026

  • 0 min

Share

  • 1

    Autologous stem-cell transplantation is essential for treating multiple myeloma, with inpatient chemo-based stem-cell mobilization being standard in Germany.

  • 2

    In a study of 109 myeloma patients, 97% achieved successful stem-cell collection, but 69% experienced severe adverse events requiring hospitalization.

  • 3

    Machine learning models were developed to predict adverse events and their onset timing, aiding in optimized ward management.

  • 4

    Risk-stratified outpatient protocols could reduce hospital bed usage by over one third without compromising patient safety.

  • 5

    Classification models effectively predicted some adverse event types, while forecasting onset timing had a mean error of just over one day.

Original Source(s)

Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma

  • by F. Schwarz, L. Levien, M. Maulhardt, G. Wulf, N. Brökers, E. Aydilek

  • February 3, 2026

Related Content

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor